Skip to content

Clinical study on rapid treatment of depression with Jiawei xiaoyao pills

Clinical study on rapid treatment of depression with Jiawei xiaoyao pills

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083381
Enrollment
Unknown
Registered
2024-04-23
Start date
2024-04-28
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

treatment group:Take Jiawei xiaoyao pills twice a day, 6g a time.
control group:Take Sertraline tablets one or twice a day, 50mg-200mg a time.

Sponsors

The people’s hospital of Danzhai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the DSM-V or ICD-10 diagnostic criteria for depression; 2. Patients with mild to moderate depression aged 12-75 years; 3. Patients with mild to moderate depression, Hamilton Depression Scale (24 items) score 35 points =HAMD-24=20 points; Montgomery Depression Rating Scale score 30 points =MADRS score =12 points; 4. Patients who have not used any Chinese medicine (including mind-soothing Chinese patent medicine and decoction) or Western medicine (Prozac, Lysopol, Bolaxin, etc.) for depression treatment in the past 1 week, or have taken the above drugs within a short period (3-5 days), and have stopped using them for more than 7 days; 5. Subjects who are willing to receive treatment for 42 days should give informed consent and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with suicidal depression, i.e., the third item score of Hamilton Depression Scale =2 points; 2. Currently suffering from other mental diseases other than depression, as well as external environmental interference factors or craniocerebral trauma caused; 3. Pregnant or lactating women; 4. People with a history of drug allergy; 5. Under the age of 12 or over the age of 75; 6. Patients with severe primary diseases of cardiovascular, lung, liver, kidney and hematopoietic system and severe organic brain diseases and mental disorders; 7. Alcohol and/or psychoactive substance, drug abusers and dependent persons (including sleeping pills); 8. Those who do not meet the inclusion criteria, do not use drugs according to regulations, cannot judge the efficacy or incomplete data affect the efficacy and safety judgment; 9. Those who cannot understand the content of the scale due to consciousness, language barriers, and insufficient intellectual and cultural level; 10. During the washout period (7 days), the patient's depressive symptoms returned to a healthy state, that is, the Hamilton Depression Scale score =20 after the washout period; 11. Patients who have had the disease for more than 2 years.

Design outcomes

Primary

MeasureTime frame
HAMD-24;

Secondary

MeasureTime frame
BDNF of serum;MADRS;QIDS-SR16;PHQ-9;Traditional Chinese Medicine Constitution Classification Scoring Scale;

Countries

China

Contacts

Public ContactLong Wenkai

The people’s hospital of Danzhai

1419185303@qq.com+86 182 8556 9010

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026